Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-reduced versus standard conditioning before allogeneic stem cell transplantation for MDS or secondary AML
NL-OMON31335Phase 3Withdrawn
- Sponsor
- EBMT
- Start
- Sep 2007
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of busulfan, cyclophosphamide and fludarabine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (2 arms), sponsored by EBMT. Primary endpoint: Non-relapse mortality at 1 year. Planned start Sep 2007; status: withdrawn.
02
Drugs
busulfancyclophosphamidefludarabine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON31335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31335.